Compare Twist Bioscience Corp (TWST) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Williams-Sonoma, Inc. — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.26B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.80B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.2× Twist Bioscience Corp's market cap, and Williams-Sonoma, Inc. pays a 1.34% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WSM | |
|---|---|---|
Market Cap | $8.26B | $26.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $251.81 |
52-Week Low | $24.16 | $168.64 |
Enterprise Value | $8.18B | $27.30B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.10 beating expectations of $2.08. Revenue trends show stabilization around $7.7-8.0B with improving net margins to 14.73%. Technical indicators show the stock testing support at $225 with RSI at oversold levels, suggesting potential near-term bounce.
The outlook remains positive with analyst consensus target of $252.23 representing 10.7% upside. Strong market share gains in home furnishings and raised full-year guidance support bullish case, though tariff pressures and competitive retail environment present ongoing risks. Institutional buying activity, including HSBC's 12.1% position increase, reinforces confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
